Download PDF
Thromb Haemost 1988; 59(02): 180-185
DOI: 10.1055/s-0038-1642750
Original Articles
Schattauer GmbH Stuttgart

Prostacyclin Release in the Coronary Circulation During Sustained Stimulation in In Vitro and in In Vivo Experimental Systems

M Prosdocimi
The Fidia Research Laboratories, Abano Terme, Italy
,
M Finesso
The Fidia Research Laboratories, Abano Terme, Italy
,
N Banzatto
The Fidia Research Laboratories, Abano Terme, Italy
,
A Zanetti
*   The Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
,
G de Gaetano
*   The Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
°   Centro di Ricerche Biomediche e Farmacologiche “Mario Negri Sud”, 66030 S. Maria Imbaro, Italy
,
E Dejana
*   The Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
› Author Affiliations
Further Information

Publication History

Received 17 April 1987

Accepted after revision 05 November 1987

Publication Date:
21 May 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Prostacyclin release from rat isolated perfused hearts and from dog coronary circulation was studied by measuring immunoreac- tive 6-keto-PGFlalpha (6-keto-PGFla) in heart perfusate and in plasma obtained from the great cardiac vein respectively.

Keywords

Prostacyclin - Cardiac ischemia - Arachidonic acid - Lactate extraction
 

  • References

  • 1 Lefer AM, Ogletree ML, Smith JB, Silver MJ, Nicolaou KC, Barnette WE, Gasic CP. Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia. Science 1978; 200: 52-54
    CrossrefPubMedGoogle Scholar
  • 2 Ribeiro LG T, Brandon TA, Hopkins DG, Reduta LA, Taylor AA. Prostacyclin in experimental myocardial ischemia: effects on hemodynamics, regional myocardial blood flow, infarct size and mortality. Am J Cardiol 1981; 47: 835-840
    CrossrefPubMedGoogle Scholar
  • 3 Aiken JW, Shebuski RJ, Miller OV, Gorman RR. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis. J Pharmacol Exp Ther 1981; 219: 299-308
    PubMedGoogle Scholar
  • 4 Romson JL, Haack DW, Abrams GD, Lucchesi BR. Prevention of occlusive coronary artery thrombosis by prostacyclin infusion in the dog. Circulation 1981; 64: 906-914
    CrossrefPubMedGoogle Scholar
  • 5 Coker SJ, Parratt JR, Ledingham IMcA, Zeitlin IJ. Thomboxane and prostacyclin release from ischemic myocardium in relation to arrhythmias. Nature 1981; 291: 323-324
    CrossrefPubMedGoogle Scholar
  • 6 Bush LR, Campbell WB, Buja LM, Tilton GD, Willerson JT. Effect of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries. Circulation 1984; 69: 1161-1170
    CrossrefPubMedGoogle Scholar
  • 7 Prosdocimi M, Finesso M, Gorio A, Languino LR, Del Maschio A, Castagnoli MN, de Gaetano G, Dejana E. Coronary and systemic 6-ketoprostaglandin Fla and thromboxane B2 during myocardial ischemia in dog. Am J Physiol 1985; 248: H493-H499
    PubMedGoogle Scholar
  • 8 Hirsch PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 1981; 304: 685-691
    CrossrefPubMedGoogle Scholar
  • 9 Ham EA, Egan RW, Soderman DD, Gale PH, Kuehl Jr FA. Peroxidase-dependent deactivation of prostacyclin synthetase. J Biol Chem 1979; 254: 2191-2194
    PubMedGoogle Scholar
  • 10 Egan RW, Gale PH, Baptista EM, Kennicott KL, Van den Heuvel WJ A, Walker RW, Fagerness PE, Kuehl Jr FA. Oxidation reactions by prostaglandin cyclooxygenase-hydroperoxidase. J Biol Chem 1981; 256: 7352-7361
    PubMedGoogle Scholar
  • 11 Dejana E, Balconi G, De Castellarnau C, Barbieri B, Vergara- Dauden M, de Gaetano G. Prostacyclin production by human endothelial and bovine smooth muscle cells in culture. Effect of repeated stimulation with arachidonic acid, thrombin and ionophore A23187 Biochim Biophys Acta 1983; 750: 261-267
    CrossrefPubMedGoogle Scholar
  • 12 Brotherton AF A, Hoak JC. Prostacyclin biosynthesis in cultured vascular endothelium is limited by deactivation of cyclooxygenase. J Clin Invest 1983; 72: 1255-1261
    CrossrefPubMedGoogle Scholar
  • 13 Vergara-Dauden M, Balconi G, Breviario F, Chiabrando C, de Gaetano G, Dejana E. Further studies on the mechanism of action of human plasma in stimulating prostacyclin production by rat smooth muscle cells. Thromb Haemostas 1985; 53: 372-376
    PubMedGoogle Scholar
  • 14 Kent RS, Diedrich SL, Whorton AR. Regulation of vascular prostaglandin synthesis by metabolites of arachidonic acid in perfused rabbit aorta. J Clin Invest 1983; 72: 455-465
    CrossrefPubMedGoogle Scholar
  • 15 Ritter JM. Prostanoid synthesis by aortic rings in human blood: selective increase of prostacyclin mediated by a serum factor. Br J Pharmac 1984; 83: 409-418
    CrossrefPubMedGoogle Scholar
  • 16 Boeynaems JM, Galand N, Ketelbant P. Prostacyclin production by the deendothelialized rabbit aorta. J Clin Invest 1985; 76: 7-14
    CrossrefPubMedGoogle Scholar
  • 17 Deckmyn H, Van Houtte E, Verstraete M, Vermylen J. Manipulation of the local thromboxane and prostacyclin balance in vivo by the antithrombotic compounds dazoxiben, acetylsalicylic acid and nafazatrom. Biochem Pharmacol 1983; 32: 2757-2762
    CrossrefPubMedGoogle Scholar
  • 18 Patrono C, Pugliese F, Ciabattoni G, Patrignani P, Maseri A, Chierchia S, Peskar BA, Cinotti GA, Simonetti BA, Pierucci A. Evidence for a direct stimulatory effect of prostacyclin on renin release in man. J Clin Invest 1982; 69: 231-239
    CrossrefPubMedGoogle Scholar
  • 19 Kahlen T, Schror K. Mepindolol protection of prostacyclin formation. Subsequent increase in arachidonic acid-induced prostacyclin release in isolated guinea pig heart Eur J Pharmacol 1982; 82: 81-84
    CrossrefPubMedGoogle Scholar
  • 20 Deckmyn H, Gresele P, Arnout J, Todisco A, Vermylen J. Prolonging prostacyclin production by nafazatrom or dipyridamole. Lancet 1984; II: 410-411
    PubMedGoogle Scholar
  • 21 Belo SE, Talesnik J. Coronary vasoconstrictor and vasodilator actions of arachidonic acid in the isolated perfused heart of the rat. Br J Pharmac 1982; 75: 269-286
    CrossrefPubMedGoogle Scholar
  • 22 Karmazyn M, Moffat MP. Toxic properties of arachidonic acid in normal, ischemic and reperfused hearts. Indirect evidence for free radical involvement Prostaglandins, Leukotrienes and Medicine 1985; 17: 251-264
    CrossrefPubMedGoogle Scholar
  • 23 Ingerman-Wojenski C, Silver MJ, Smith JB, Nissenbaum M, Sedar AW. Prostacyclin production in rabbit arteries in situ: inhibition by arachidonic acid-induced endothelial cell damage or by low-dose aspirin. Prostaglandins. 1981; 21: 655-666
    PubMedGoogle Scholar
  • 24 Moncada S, Palmer RM J, Higgs EA. Prostacyclin and endothelium- derived relaxing factor: biological interactions and significance. In: Thrombosis and Haemostasis. Verstraete M, Vermylen J, Lijnen HR, Arnout J. eds. Leuven University Press; Leuven: 1987. pp 597-618
    Google Scholar
  • 25 Karmazyn M. Contribution of prostaglandins to reperfusion-induced ventricular failure in isolated rat hearts. Am J Physiol 1986; 251: H133-H140
    PubMedGoogle Scholar
  • 26 Moffat MP. Concentration-dependent effects of prostacyclin on the response of the isolated guinea pig heart to ischemia and reperfusion: possible involvement of the slow inward current. J Pharmacol Exp Ther 1987; 242: 292-299
    PubMedGoogle Scholar
  • 27 Frangos JA, Eskin SG, Mclntire LV, Ives CL. Flow effects on prostacyclin production by cultured human endothelial cells. Science 1985; 227: 1477-1479
    CrossrefPubMedGoogle Scholar
  • 28 Basu DK, Karmazyn M. Injury to rat hearts produced by an exogenous free radical generating system. Study into the role of arachidonic acid and eicosanoids. J Pharmacol Exp Ther 1987; 242: 673-685
    PubMedGoogle Scholar
  • 29 Taylor BM, Shebuski RJ, Sun FF. Circulating prostacyclin metabolites in the dog. J Pharmacol Exp Ther 1983; 224: 692-698
    PubMedGoogle Scholar
  • 30 FitzGerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-989
    CrossrefPubMedGoogle Scholar
  • 31 Opie HL. Effects of regional ischemia on metabolism of glucose and fatty acids. (Relative rates of aerobic and anaerobic energy production during myocardial infarction and comparison with effects of anoxia.) Circ Res 1976; 38: I52-I74
    PubMedGoogle Scholar
  • 32 Khuri SF, Kloner RA, Karaffa SA, Marston W, Taylor AD, Lai NC J, Tow DE, Barsamian E. The significance of the late fall in myocardial Pco2 and its relationship to myocardial pH after regional coronary occlusion in the dog. Circ Res 1985; 56: 537-547
    CrossrefPubMedGoogle Scholar
  • 33 Wu KK, Papp AC, Manner CE, Hall ER. Interaction between lymphocytes and platelets in the synthesis of prostacyclin. J Clin Invest 1987; 79: 1601-1606
    CrossrefPubMedGoogle Scholar
  • 34 Marcus AJ, Weksler BB, Jaffe EA, Broekman MJ. Synthesis of prostacyclin from platelet derived endoperoxides by cultured human endothelial cells. J Clin Invest 1980; 66: 979-986
    CrossrefPubMedGoogle Scholar
  • 35 Rossi V, Breviario F, Ghezzi P, Dejana E, Mantovani A. Prostacyclin synthesis induced in vascular cells by interleukin-1. Science 1985; 229: 174-176
    CrossrefPubMedGoogle Scholar
  • 36 Malliani A. Cardiovascular sympathetic afferent fibers. Rev Physiol Biochem Pharmacol 1982; 94: 11-74
    PubMedGoogle Scholar
  • 37 Coker SJ, Parratt JR. Prostacyclin-antiarrhythmic or arrhyth- mogenic? Comparison of the effects of intravenous and intracoronary prostacyclin and ZK 36374 during coronary artery occlusion and reperfusion in anesthetized greyhounds. J Cardiovasc Pharmacol 1983; 5: 557-567
    CrossrefPubMedGoogle Scholar